A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

• Status: Completed
• Trial end date: 2020-02-10
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety and tolerability of multiple doses of BMS-963272 in obese but otherwise healthy participants.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Participants must be in good general health, in the opinion of the investigator, with no clinically significant deviation from normal in medical history, physical examination findings, ECGs, or laboratory results.

• Participants must have a BMI of 30 kg/m2 to 40 kg/m2 inclusive

• Women (not of childbearing potential) and men aged 18 to 60 years, inclusive

Exclusion Criteria:

• Previous participation in the current study

• Inability or unwillingness to comply with protocol-defined restrictions or requirements regarding lifestyle, diet, concomitant medications, or other aspects of the study

• Inability to tolerate the oLTT meal or to comply with oLTT testing conditions

• Inability to tolerate oral medication

• Inability to tolerate venipuncture and/or inadequate venous access

• Women who are breastfeeding

• Medical Conditions

• History of lactose intolerance

• Any significant (in the opinion of the investigator) acute or chronic illness

• Type 1 or 2 diabetes

• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population

• Previous/Concomitant Therapy

• Previous exposure to BMS-963272

Other protocol-defined inclusion/exclusion criteria could apply